ReviewCurrent hypertension reviews2026
The Mechanisms and Treatment Approaches of Oxidative Stress and Inflammation in the Development of Chronic Kidney Disease.
Review in Current hypertension reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The article investigates the crucial roles of oxidative stress and inflammation in the progression of Chronic Kidney Disease (CKD), a condition that poses an increasing global health burden. An imbalance between reactive oxygen species (ROS) and antioxidant defenses leads to mitochondrial damage, which subsequently triggers endothelial dysfunction and promotes kidney fibrosis. CKD symptoms are further exacerbated by inflammation, driven by uremic toxins and cytokine activity. The article highlights NF-κB and Nrf2 as key signaling pathways that regulate these networks. Additionally, it examines how cardiovascular disease, mineral-bone disorder, and cognitive decline emerge as clinical consequences of inflammatory and oxidative tissue damage. Therapeutic strategies for CKD are categorized into three main approaches: antioxidants and antiinflammatory medications, SGLT2 inhibitors, and bardoxolone methyl. The article also emphasizes non-pharmacological interventions, including behavioral modifications, dietary adjustments, probiotic use, and modulation of the gut microbiota. Finally, it discusses emerging research on biomarker development, precision medicine techniques, and genetic therapies aimed at improving CKD detection, management, and treatment outcomes.
Indexed as
Identifiers
42099176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.